In conclusion, our results proposed a novel regulatory mechanism driving NSCLC metastasis fostered by deregulation of miR-124 comprising of IL-6/NF-κB upstream inhibitory signal and MYO10 downstream executioners, providing an opportunity to develop new effective clinical therapies for NSCLC. Here, MYO10 is linked to non-small cell lung carcinoma.